Press Releases

Pharmacierge, the leader in private e-prescription app and delivery services announces its forthcoming expansion within the heart of London’s healthcare district.  The expansion includes an extensive new 5,500 sqft dispensary equipped with a 30ft dispensing robot, both the largest of their kind in the prestigious Harley Street Medical Area (HSMA).  Pharmacierge is itself backed by 80 leading private GPs and Consultants spanning all medical specialties. Acquiring the

Novartis, a global leader in immuno-dermatology and rheumatology, has received approval from the US Food and Drug Administration (FDA) for an intravenous (IV) formulation of Cosentyx® (secukinumab). This approval extends the usage of Cosentyx to treat adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx is the only treatment with an approved IV formulation that specifically targets and blocks interleukin-17A

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced, its initiative to utilize Artificial Intelligence to both screen its current pipeline as well as utilize AI for licensing opportunities in acquiring or partnering novel therapeutics for rare diseases. Hoth will form and operate a new wholly owned subsidiary named Merveille.ai, which will focus on screening for collaborative opportunities utilizing Artificial Intelligence in the fiel

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company), a pre-revenue stage biopharmaceutical company focused on development of a potential treatment for osteoarthritis as part of its OA-201 program, today announced that it has selected Ascendia Pharmaceuticals, Inc. ("Ascendia") to provide services to support the clinical development of OA-201, a novel therapeutic for the treatment of symptomatic osteoarthritis pain. OA-201 consists of a natural metabolite, formulate

Eurofins CDMO Alphora Inc. is pleased to announce the launch of its Biologics initiative, as part of its vision to diversify and grow within the contract development and manufacturing industry in North America. The multiphase initiative aims to establish a facility at the 2070 Hadwen site within the Sheridan Research Park campus in Mississauga, ON, Canada. The first phase of the project, scheduled for completion by December 2023, is a 3,300 square foot pilot scale facility focused on mammalia

Sosei Group Corporation ("Sosei Heptares"; TSE: 4565) and Verily, an Alphabet precision health technology company, today announced the successful validation and nomination of a first G-protein-coupled receptor (GPCR) target into early drug discovery for immune-mediated diseases with an initial indication focus of inflammatory bowel disease (IBD). This scientific breakthrough between the companies is the first research milestone stemming from the strategic collaboration ann

Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today the publication of proof-of-concept data for its oral MEK inhibitor, zapnometinib, in hospitalized patients with moderate-to-severe COVID-19 in the journal eClinicalMedicine. The double-blind, placebo-controlled RESPIRE trial investigated the safety and efficacy of zapnometinib in hospitalized adults with COVID-19 at 17 sites worldwide. The trial wa

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it has completed its previously announced merger with Morphimmune. “This merger is an essential step in establishing a preeminent oncology company,” said Dr. Siegall. “We believe that we are well positioned to advance our current oncology pipeline into the clinic, build upon the pipeline through our technology

Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company, and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that they have entered into an exclusive licensing agreement for ADL018 (also called AVT23), a proposed biosimilar to Xolair® (omalizumab), which is in clinical development. The agreement covers all 27 countries of the Europ

DSM and Firmenich – in May 2023, dsm-firmenich will make its debut at CPHI Barcelona 2023, showcasing its combined strength as an innovator in health, nutrition and care. The company, which has shared sales of more than €12 billion and a workforce of almost 30,000 employees, will demonstrate how its growing portfolio of high-quality products, customized solutions and expert services are poised to fuel purpose-driven innovation in the pharmaceutical industry. With a long-standing hi